Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Neurizon Therapeutics Ltd

NUZ.AX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Micro Cap Analyst: STRONG BUY

Last Close

$0.04

▲ +1.75%

Market Cap $33.59M · Vol 1.13M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$33.59M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

12.50

Momentum

Beta

1.36

vs Market

52W High

$0.08

52.04% below

52W Low

$0.04

3.37% above

Volume

1.13M

Avg 602.35K

P/B

3.60

Price-to-book

ROE

N/A

Return on equity

Free Float

67.86%

Public shares

Shariah Compliance8 STANDARDS

✗ Neurizon Therapeutics Ltd (NUZ.AX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NUZ.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.38%

-31.76%

-4.92%

-15.94%

YTD

-31.76%

-43.82%

-31.02%

-50.84%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,419,235.00
Revenue Growth (YoY)	+872.22%
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-76.44% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.60
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	855.37M

Technical Indicators

50-Day SMA	$0.05
200-Day SMA	$0.05
RSI (14)	12.50
Beta	1.36
52-Week High	$0.08
52-Week Low	$0.04

Volume Today	1.13M
Avg Daily Volume (30D)	602.35K
Relative Volume	1.88x
Volatility (10D)	135.77
Volatility (30D)	95.11
Free Float	67.86%

Analyst Consensus

STRONG BUY

Current Price $0.04

Mean Target $0.14

52W Low$0.04 52W High$0.08

Current

Target

$0.04 $0.08

Current Analyst target

+264.79% upside potential · 1 analysts

Identifiers

ExchangeASX

FIGIBBG001SC5SW8

ISINAU0000357261

CountryAustralia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateFeb 23, 2027

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Company +1.14% JNJ Johnson & Johnson +0.79% ABBV AbbVie Inc. +0.20% NVS Novartis AG +0.16% NOVN.S Novartis AG -0.12%

Company Profile

Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. It is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.